Washington, DC. – 264 vaccines in the pipeline. $173b saved in cancer-related costs. 883,000 fewer hospitalizations per year. These are just a few of the many stats The Biotechnology Innovation Organization (BIO) promotes on their new website, innovationsaves.life and many that never make it to the surface of our daily lives. BIO also brings in the human aspect of the pharmaceutical R&D landscape and how these innovations are saving lives. And to help bring these innovations to the surface, BIO is betting big, at the tune of a $1-$5 million ad campaign, to help bring awareness and defend pharmaceutical pricing models.

These innovations are going to be needed by all of us — our sons and daughters, your mother, your father, neighbors, friends, yourself. Ron Cohen, M.D. – President & CEO of Acorda Therapeutics; Chair, BIO


Why it Matters:

This is a prime example of humanizing the pharmaceutical process/pricing model and telling the whole story to help us understand what goes on behind the scenes and why we do what we do as pharmaceutical & healthcare marketing professionals. As with most stories, there are always two sides, and while there is still a needed healthy debate about specific price points (i.e. Epi-Pen), this is a great storytelling example and reminder that there is much more going on than meets the eye.

About the Author:

As Strategist of Innovation, Drew is charged daily with championing innovative thinking and doing. Drew is part of a global team that leads new innovative ideas that attract different advocates among existing and potential brands that are shared across all agency partners. Drew is backed by over 16 years of brand, sales and marketing experience with Fortune 500 companies such as Progressive and Nationwide Insurance as well as Founder & President of his own healthcare insurance agency for 6 years. Most recently Drew was part of the agency team that launched Briviact for UCB, Foundation Medicine as well as key roles with Eli Lilly Oncology and Johnson & Johnson.